Import from '@/components'

AOD-9604 and Benzodiazepines: What Every Woman Needs to Know About This Interaction

What AOD-9604 Actually Is (and What It Is Not)

AOD-9604 is a synthetic peptide corresponding to amino acids 176 to 191 of human growth hormone (hGH). It was originally developed by Metabolic Pharmaceuticals as an anti-obesity agent, and it reached Phase II clinical trials in the early 2000s before development was halted due to lack of efficacy on primary endpoints. Today it circulates widely in the compounding pharmacy and peptide research markets, marketed for fat loss, cartilage repair, and metabolic support, none of which are FDA-approved indications.

The peptide is not a controlled substance. It is not on the FDA-approved drug list. It is available through 503A compounding pharmacies, which means it is produced for individual patients under a prescriber's order but without the standard FDA new-drug-approval process. That regulatory gap matters because it also means there is no FDA-reviewed label, no standardized dosing, and no mandated drug-interaction screening.

How AOD-9604 Is Thought to Work

The proposed mechanism centers on the lipolytic region of hGH. AOD-9604 appears to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation) without the insulin-like or growth-promoting effects of full-length hGH, based on animal and early human data from the Phase I/II program. It may act through beta-adrenergic pathways and possibly through indirect modulation of IGF-1 signaling, though the exact receptor targets in humans remain incompletely characterized.

Critically, no published pharmacokinetic study has mapped AOD-9604 through the cytochrome P450 (CYP) enzyme system or characterized its P-glycoprotein (P-gp) transporter interactions in humans. This is not a minor gap. It means the metabolic basis for any drug interaction cannot be stated with certainty.

Why Women Are Using It

Women are the primary consumer base for off-label peptide therapies. A 2023 analysis of telehealth peptide prescriptions found that women accounted for the majority of GLP-1 and peptide therapy inquiries across reproductive and perimenopausal age groups. The most common reasons cited are weight loss resistance, particularly the fat redistribution that accompanies perimenopause, post-PCOS metabolic dysregulation, and postpartum weight retention.

Benzodiazepines: The Pharmacology You Need

Benzodiazepines bind to the GABA-A receptor complex and potentiate the inhibitory effect of gamma-aminobutyric acid (GABA), producing sedation, anxiolysis, muscle relaxation, and anticonvulsant effects. Common agents include diazepam (Valium), lorazepam (Ativan), clonazepam (Klonopin), and alprazolam (Xanax).

Sex-Specific Pharmacokinetics of Benzodiazepines

This section matters more than most interaction discussions acknowledge. Women are not pharmacokinetically identical to men, and the difference is clinically meaningful for benzodiazepines.

Diazepam and other highly lipophilic benzodiazepines have a larger volume of distribution in women due to higher body fat percentage, which prolongs their half-life. Estrogen inhibits CYP3A4-mediated oxidative metabolism of some benzodiazepines, slowing clearance. Studies show that women have approximately 20 to 30% lower clearance of certain benzodiazepines compared with men, which translates into higher plasma concentrations at the same weight-adjusted dose and a greater risk of oversedation and next-day cognitive impairment.

GABA-A receptor sensitivity itself fluctuates across the menstrual cycle. Allopregnanolone, a progesterone metabolite, is a potent positive allosteric modulator of GABA-A receptors. Levels of allopregnanolone rise in the luteal phase, meaning benzodiazepine effects may be amplified in the week before menstruation. During perimenopause, progesterone withdrawal reduces allopregnanolone, disrupting GABAergic tone and contributing to the insomnia and anxiety that often drive benzodiazepine prescribing in this age group.

Why Benzodiazepines Are Prescribed to Women at Higher Rates

Women are prescribed benzodiazepines at roughly twice the rate of men. The clinical drivers include higher rates of generalized anxiety disorder, panic disorder, insomnia in perimenopause, and premenstrual dysphoric disorder (PMDD). This matters for the interaction discussion because the population most likely to be taking a benzodiazepine is also the population most likely to be pursuing a peptide therapy for perimenopausal weight gain.

The Interaction Mechanism: What We Know and What We Don't

There is no published, peer-reviewed study that directly examined the pharmacokinetic or pharmacodynamic interaction between AOD-9604 and any benzodiazepine. That is the foundational clinical fact, and any source claiming otherwise is speculating or fabricating data.

What can be reasoned from first principles:

CYP Enzyme Considerations

Benzodiazepines are metabolized primarily through CYP3A4 (diazepam, alprazolam, triazolam, midazolam) and CYP2C19 (diazepam also undergoes this pathway) as documented in FDA labeling. If AOD-9604, as a peptide, induces or inhibits CYP3A4, benzodiazepine plasma levels could rise or fall. At present, no published data characterizes AOD-9604's CYP profile. Peptides are generally hydrolyzed to amino acids rather than metabolized hepatically through CYP pathways, which suggests the CYP interaction risk may be low, but this has not been confirmed experimentally.

Pharmacodynamic Considerations

This is the more plausible interaction pathway. Human growth hormone and its fragments influence central nervous system function. Full-length hGH receptors are expressed in the brain, and hGH affects sleep architecture, increasing slow-wave sleep. Research in adults shows that growth hormone secretion is tightly coupled to deep non-REM sleep. Benzodiazepines suppress slow-wave sleep. A pharmacodynamic interaction, where AOD-9604 and benzodiazepines push sleep architecture in opposite directions or where combined use disrupts normal CNS signaling, is biologically plausible, though entirely unconfirmed for AOD-9604 specifically.

Beta-Adrenergic Pathway Overlap

AOD-9604 has been proposed to act partly through beta-3 adrenergic receptors in adipose tissue. Beta-adrenergic tone influences arousal, anxiety, and cardiovascular parameters. Benzodiazepines reduce sympathetic tone. Whether simultaneous modulation of both systems produces any clinically meaningful additive or opposing effect is unknown.

The WomanRx three-tier interaction framework for off-label peptides with established drugs:

Tier 1 (Theoretical, low concern): Pharmacokinetic interaction is unlikely based on known metabolism pathways but unconfirmed. Monitor for unexpected symptom changes.

Tier 2 (Plausible, moderate concern): A mechanistic basis exists for pharmacodynamic overlap. Requires explicit prescriber discussion and possibly dose-timing separation.

Tier 3 (Documented, high concern): Published DDI data or case reports demonstrate a clinically meaningful effect. Requires dose adjustment or avoidance.

AOD-9604 combined with benzodiazepines sits at Tier 2. The pharmacodynamic overlap through CNS and sleep-architecture effects is mechanistically plausible. The absence of confirmatory data does not eliminate the risk; it eliminates the ability to quantify it.

Women-Specific Risks Across Life Stages

Reproductive Years (Ages 18 to 44)

Women in their reproductive years may be using benzodiazepines for PMDD, panic disorder, or anxiety. AOD-9604 use in this context is usually for fat-loss goals, often post-PCOS weight gain or refractory adiposity. The cyclical variation in GABA-A sensitivity described above means that any additive CNS effect of AOD-9604 may be amplified in the late luteal phase. If you are in this life stage and taking both agents, tracking symptom intensity relative to cycle day is a reasonable monitoring step.

Perimenopause (Typically Ages 40 to 55)

This is the life stage at highest combined-use risk. Perimenopausal women experience estrogen and progesterone volatility, fat redistribution to the abdomen, sleep disruption, and anxiety. These are the exact drivers of both benzodiazepine prescribing and peptide therapy use. The Menopause Society notes that sleep disturbance affects up to 47% of perimenopausal women, and benzodiazepines are frequently used as a short-term bridge before other therapies are optimized.

The progesterone withdrawal that characterizes perimenopause reduces endogenous GABAergic tone. Adding a benzodiazepine restores artificial GABAergic suppression. Introducing AOD-9604, which may influence GH-related sleep-cycle regulation, into this already disrupted hormonal environment adds a variable whose effect cannot be predicted from current data.

Post-Menopause

Post-menopausal women have lower estrogen levels and thus reduced CYP3A4 inhibition. Benzodiazepine clearance may be somewhat faster than in pre-menopausal women, but the sedation risk remains, particularly in women over 65 where the American Geriatrics Society Beers Criteria explicitly recommends against benzodiazepine use due to fall, fracture, and cognitive impairment risk. Adding any agent with unclear CNS activity in this population is inadvisable without direct clinician oversight.

PCOS

Women with PCOS have altered insulin sensitivity, higher rates of anxiety and depression, and often pursue fat-loss therapies more aggressively. Benzodiazepine use in PCOS is not uncommon given the elevated psychiatric comorbidity burden. No data addresses how PCOS-related metabolic changes might alter AOD-9604 disposition.

Pregnancy and Lactation Safety

If you are pregnant, trying to conceive, or breastfeeding, do not use AOD-9604.

This is not a nuanced statement. There is no human gestational safety data for AOD-9604. Zero. It has not been assigned an FDA pregnancy category because it was never approved. Animal reproductive toxicity studies sufficient to inform human risk have not been published. Any prescriber offering AOD-9604 to a pregnant or actively trying-to-conceive patient is operating without any safety evidence base.

Benzodiazepines carry their own gestational risks. ACOG Practice Bulletin guidance acknowledges that benzodiazepine use in the first trimester has been associated with a small increased risk of oral cleft, though the absolute risk remains low and the data are conflicting. Neonatal withdrawal syndrome is a documented risk with third-trimester benzodiazepine use. Benzodiazepines transfer into breast milk, and the NIH LactMed database rates most benzodiazepines as requiring caution during breastfeeding, with shorter-acting agents such as lorazepam preferred over longer-acting ones if use cannot be avoided.

Contraception note: Because AOD-9604 has no gestational safety data and is used off-label, women of reproductive age should use reliable contraception while taking it, consistent with the general principle applied to other investigational compounds. Discuss this requirement with your prescribing clinician.

Who This Combination Is and Is Not Right For

Not right for you if:

• You are pregnant, may be pregnant, or are trying to conceive
• You are breastfeeding
• You are over 65 and using benzodiazepines for sleep (the fall-and-fracture risk alone warrants reassessment of the benzodiazepine before adding any peptide)
• Your benzodiazepine is prescribed for active seizure control (any disruption of this medication's predictable pharmacology is unacceptable risk)
• You have not disclosed the AOD-9604 use to the clinician prescribing your benzodiazepine, or vice versa

Potentially manageable if:

• You are in a stable reproductive-age window, not pregnant or trying to conceive, using benzodiazepines short-term and intermittently
• Both agents are prescribed or supervised by a clinician who is aware of both and has documented the rationale
• You have a clear monitoring plan for sedation, cognitive changes, sleep quality, and cycle-phase symptom variation
• You are not using additional CNS-active agents (alcohol, opioids, antihistamines, muscle relaxants, or other sedatives) that compound the CNS burden

What to Tell Your Clinician

Women often underreport peptide and supplement use to prescribers, sometimes because they anticipate dismissal or because the compounds feel low-risk due to their off-label status. This is a real patient-behavior pattern, and it creates a genuine safety gap.

Before combining AOD-9604 with a benzodiazepine, bring both prescriptions (or orders) to a single clinician visit and ask these specific questions:

1. What CYP pathway does my specific benzodiazepine use for metabolism, and could AOD-9604 affect it?
2. Given my hormonal status (menstrual cycle phase, perimenopausal, post-menopausal), am I at higher risk for sedation with this combination?
3. Is there a safer alternative to my benzodiazepine for my underlying indication, now that I am also using a peptide with unknown CNS effects?
4. What symptoms should prompt me to stop one or both agents immediately?

A prescriber who cannot engage with these questions is not an appropriate source for either agent.

Monitoring and Practical Safety Steps

If a clinician has reviewed both agents and determined the combination is acceptable for your situation, these are reasonable monitoring practices:

• Track daytime sedation daily for the first two weeks using a simple 1 to 10 scale
• Note any changes in coordination or reaction time, particularly relevant if you drive or operate equipment
• Log sleep quality (not just duration) because the opposing sleep-architecture effects of GH-related peptides and benzodiazepines may produce subjective sleep changes without obvious sedation
• Track cycle day alongside symptom intensity during your first two to three cycles on the combination, noting any amplification in the late luteal phase
• Report any new anxiety, rebound insomnia, or mood changes promptly, as these may indicate tolerance or withdrawal phenomena from the benzodiazepine that are being masked or unmasked by the peptide

The FDA MedWatch program accepts voluntary reports for adverse events involving compounded products, including peptides. Filing a MedWatch report when you experience an unexpected effect contributes to the limited safety signal pool for unregulated compounds.

The Evidence Gap: An Honest Assessment

Women have been historically under-represented in drug interaction studies, and peptide research compounds like AOD-9604 have essentially no sex-stratified pharmacokinetic data at all. The interaction literature for this combination does not exist in any form that meets the standard for clinical practice guidance.

The FDA has noted in multiple guidance documents that sex differences in drug metabolism are clinically meaningful and that approval studies failing to stratify by sex may underestimate risk in women. For a compound like AOD-9604 that never completed a Phase III approval pathway, this gap is not merely an academic concern. It is a live safety issue for every woman using it.

What is directly studied: benzodiazepine sex-specific pharmacokinetics, GABA-A receptor sensitivity across the menstrual cycle, and the relationship between growth hormone and sleep architecture, all cited above.

What is extrapolated: the application of those mechanisms to AOD-9604 specifically, the assumption that AOD-9604's CNS effects parallel those of full-length hGH, and the clinical significance of any pharmacodynamic interaction.

Be clear-eyed about which category your prescriber is drawing from when they advise you.